MYELO THERAPEUTICS:


Associated tags: SDAX, Mortality, ISIN, Medicine, Acute radiation syndrome, Radiation, Deutsch, NIAID, ARS, Nuclear medicine, MCM, Subacute myelo-optic neuropathy, Pharmaceutical industry, Medical imaging, Radiation Sickness, Infection, Toxicity

DGAP-News: Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures

Retrieved on: 
Donnerstag, August 4, 2022
Microsoft, Acute radiation syndrome, Infection, Radiation Sickness, Epidemic, Wastewater treatment, Subacute myelo-optic neuropathy, MCM, Nuclear medicine, National, Joint Chemical, Biological, Radiological and Nuclear Regiment, Industry, Program, Research, Commissariat, CEA, Radiation, National Institute, NATO, Medicine, ISIN, Therapy, Mortality, Toxicity, SDAX, CRBN, Deutsch, NIAID, ARS, Pharmaceutical industry, Medical imaging, EU, Chemical substance, Nuclear

The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.

Key Points: 
  • The current program has the potential to advance its MCM candidate towards a marketing authorization application at the end of the four-year funding period.
  • Beyond its potential as a medical countermeasure, the MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality.

DGAP-News: Eckert & Ziegler Affiliate Receives Further NIAID Funding for Clinical Development

Retrieved on: 
Donnerstag, Juli 21, 2022
Rabbit, National, Toxicity, Mortality, Acute radiation syndrome, Deutsch, Red blood cell, Industry, Neutrophil, ISIN, NIAID, Temperature, Radiation, National Institute, MCM, RIM, Infection, Medicine, ARS, Nuclear medicine, Subacute myelo-optic neuropathy, Lymphocyte, Blood, Survival, Mouse, Gesellschaft mit beschränkter Haftung, SDAX, Radiation Sickness, CIM, Pharmaceutical industry, Medical imaging

Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.

Key Points: 
  • Preclinical and clinical studies have shown that Myelo001 has prophylactic and therapeutic efficacy in reducing hematopoietic symptoms caused by radiation and chemotherapy.
  • Comprehensive chronic toxicology and safety studies, as well as clinical studies, have confirmed Myelo001s excellent safety profile.
  • About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AG with its 900 employees, is a leading global specialist for isotope-related applications in nuclear medicine, industry, and radiation therapy.
  • Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Brse.